Skip Navigation



Annals of Oncology Advance Access published online on January 19, 2006
Annals of Oncology, doi:10.1093/annonc/mdj134
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/4/614    most recent
mdj134v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Marty, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marty, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received April 14, 2005
Revised November 21, 2005
Accepted December 2, 2005

original article

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy

M. Marty 1 *, M. Espié 1, A. Llombart 2, A. Monnier 3, B. L. Rapoport 4, V. Stahalova 5, and On behalf of the Dexrazoxane Study Group

1 Hôpital Saint Louis, Paris, France
2 Instituto Valenciano de Oncología, Valencia, Spain
3 Centre Hospitalier André Boulloche, Montbéliard, France
4 Medical Oncology Centre of Rosebank, Johannesburg, South Africa
5 Hospital Bulovka, Prague, Czech Republic

* To whom correspondence should be addressed.
M. Marty, E-mail: m.marty{at}sls.aphp.fr


  Abstract

Background: Anthracycline-induced cardiotoxicity has led to the adoption of empirical dose limits that may restrict continued use of anthracyclines among patients who might benefit. Dexrazoxane, a cardioprotective agent, has been shown to reduce the risk of anthracycline-associated cardiotoxicity when given from first dose of anthracycline. This study sought to confirm the benefit of dexrazoxane in patients at high risk of cardiotoxicity due to prior anthracycline use.

Patients and methods: A total of 164 female breast cancer patients, previously treated with anthracyclines, received anthracycline-based chemotherapy either with (n = 85) or without (n = 79) dexrazoxane for a maximum of six cycles.

Results: Compared with those receiving anthracycline alone, patients treated with dexrazoxane experienced significantly fewer cardiac events (39% versus 13%, P < 0.001) and a lower and less severe incidence of congestive heart failure (11% versus 1%, P < 0.05). Tumor response rate was unaffected by dexrazoxane therapy. The frequency of adverse events was similar between groups and there were no significant between-group differences in the number of dose modifications/interruptions.

Conclusion: Dexrazoxane significantly reduced the occurrence and severity of anthracycline-induced cardiotoxicity in patients at increased risk of cardiac dysfunction due to previous anthracycline treatment without compromising the antitumor efficacy of the chemotherapeutic regimen.

Keywords: anthracycline; breast cancer; cardioprotection; clinical trial; dexrazoxane.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
L. Willems, F. Suarez, N. Baubion, D. Decaudin, D. Ghez, O. Hermine, B. Varet, and M.-T. Rubio
High risk of cardiac dysfunction after treatment of secondary acute myeloid leukaemia to breast cancer
Ann. Onc., March 1, 2009; 20(3): 597 - 599.
[Full Text] [PDF]

Home page
 JCOHome page
L. Gianni, E. H. Herman, S. E. Lipshultz, G. Minotti, N. Sarvazyan, and D. B. Sawyer
Anthracycline Cardiotoxicity: From Bench to Bedside
J. Clin. Oncol., August 1, 2008; 26(22): 3777 - 3784.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Hellmann
Dexrazoxane-Associated Risk for Secondary Malignancies in Pediatric Hodgkin's Disease: A Claim Without Evidence
J. Clin. Oncol., October 10, 2007; 25(29): 4689 - 4690.
[Full Text] [PDF]

Home page
 JCOHome page
S. E. Lipshultz, S. R. Lipsitz, and E. J. Orav
Dexrazoxane-Associated Risk for Secondary Malignancies in Pediatric Hodgkin's Disease: A Claim Without Compelling Evidence
J. Clin. Oncol., July 20, 2007; 25(21): 3179 - 3179.
[Full Text] [PDF]

Home page
 Mol. Interv.Home page
Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield, and D. K. St. Clair
Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues
Mol. Interv., June 1, 2007; 7(3): 147 - 156.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Sterba, O. Popelova, T. Simunek, Y. Mazurova, A. Potacova, M. Adamcova, H. Kaiserova, P. Ponka, and V. Gersl
Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity
J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1336 - 1347.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.